Key Points
- CEO Martine Rothblatt sold 9,500 shares on April 20 at an average price of $577.83 for about $5.49M, cutting her stake by roughly 19% to 40,513 shares (worth ~ $23.41M).
- The CFO (10,000 shares, ~ $5.78M) and another director (≈ $578.9k) also sold recently, creating a cluster of senior‑executive disposals that could pressure near‑term sentiment.
- Despite the insider sales, analysts remain broadly constructive with a consensus "Moderate Buy" and an average price target near $601.50, while UTHR trades close to its 52‑week high and has a market cap of about $25.1B.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction on Monday, April 20th. The stock was sold at an average price of $577.83, for a total value of $5,489,385.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $23,409,626.79. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
United Therapeutics Stock Performance
UTHR opened at $573.46 on Wednesday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $607.89. The stock's fifty day moving average is $530.74 and its 200-day moving average is $492.11. The company has a market capitalization of $25.13 billion, a PE ratio of 20.55, a P/E/G ratio of 1.63 and a beta of 0.75.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the business earned $6.19 EPS. The company's quarterly revenue was up 7.4% compared to the same quarter last year. On average, equities research analysts forecast that United Therapeutics Corporation will post 27.93 EPS for the current fiscal year.
Institutional Investors Weigh In On United Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. Torren Management LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management raised its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $31,000. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics during the fourth quarter valued at $48,000. 94.08% of the stock is owned by institutional investors and hedge funds.
United Therapeutics News Summary
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: New clinical and program data to be presented at ISHLT (ARTISAN and PHINDER interim analyses) highlight earlier detection/management of pulmonary hypertension, right‑ventricular improvement with high‑dose treprostinil, and progress on lung donor expansion/xenotransplantation — supports pipeline value and longer‑term revenue upside. Read More.
- Positive Sentiment: Analyst sentiment remains constructive with several recent price‑target raises and a consensus “Moderate Buy” and average target around $601.50 — provides valuation support if clinical readouts impress. Read More.
- Positive Sentiment: Discussion that the bull case for UTHR could materially change if miroliverELAP obtains FDA RMAT status — a regulatory win like RMAT would be a strong catalyst for re‑rating the pipeline. Read More.
- Neutral Sentiment: A comparative valuation article (CPRX vs UTHR) offers context for value investors but is unlikely to move UTHR materially on its own. Read More.
- Neutral Sentiment: Asset Management One modestly trimmed its stake (down ~5.1%), a small institutional reweighting rather than a major flow signal. Read More.
- Neutral Sentiment: Reports of unusually large options activity indicate elevated short‑term trading/hedging interest — this can amplify intraday moves but is directionally ambiguous. Read More.
- Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.49M on Apr 20), reducing her stake by ~19% — a high‑profile insider sale that often raises investor concern about near‑term sentiment. Read More.
- Negative Sentiment: CFO James Edgemond sold 10,000 shares (~$5.78M) on Apr 20, leaving a significantly smaller holding — multiple senior exec sales in quick succession increase perceived selling pressure. Read More.
- Negative Sentiment: Additional director insider sale (~$578.9k) and prior smaller CEO disposals add to the pattern of recent insider liquidations, which can weigh on near‑term stock sentiment. Read More.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on the company. Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research report on Tuesday, March 31st. Bank of America boosted their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 31st. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Finally, Morgan Stanley boosted their target price on United Therapeutics from $471.00 to $519.00 and gave the stock an "equal weight" rating in a research report on Friday, April 10th. Ten equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $601.50.
View Our Latest Report on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
